Hyzaar

Losartan potassium and hydrochlorothiazide, the active ingredients in Hyzaar, are an angiotensin II receptor blocker and a thiazide diuretic presented as tablets for oral use. They treat hypertension and associated edema in adult patients.

GNH USA supplies Hyzaar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hyzaar is an antihypertensive combination that acts on the renin‑angiotensin system and renal sodium handling.

Hypertension: lowers systolic and diastolic blood pressure in adults. Edema associated with hypertension: reduces fluid accumulation and peripheral swelling. Cardiovascular risk reduction: contributes to lower incidence of stroke and myocardial infarction in patients with high blood pressure.

Hyzaar may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urinary frequency - Mild electrolyte disturbances (e.g., low potassium) - Transient rise in serum creatinine

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension, especially after volume depletion - Hyperkalemia (high potassium levels) - Acute renal failure or marked decline in kidney function - Severe dehydration - Pancreatitis (rare)

Before initiating Hyzaar, clinicians should evaluate patient‑specific factors and monitor therapy.

Monitor blood pressure: ensure adequate control without excessive hypotension. Assess renal function: check serum creatinine and eGFR periodically. Check electrolytes: especially potassium and sodium levels. Avoid use in pregnancy: drug is classified as Category D and may cause fetal harm. Use caution in elderly patients: increased sensitivity to blood‑pressure lowering effects. Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Hyzaar can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade may cause renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., beta‑blockers, calcium channel blockers): additive blood‑pressure lowering effect; monitor for hypotension. - CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may increase losartan plasma levels; adjust dose if needed.